TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) is a clinical‐stage biopharmaceutical company focused on the discovery and development of precision therapies that leverage the biology of tumor necrosis factor (TNF) pathways. The company aims to create novel treatments for immune‐mediated inflammatory disorders as well as select oncology indications. Its research platform integrates advanced molecular screening, synthetic biology, and translational immunology to identify and optimize drug candidates that can modulate TNF signaling with enhanced specificity and safety profiles.
The company’s pipeline includes multiple therapeutic candidates in various stages of development. Lead programs are advancing through preclinical and early clinical trials in indications such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. TNF Pharmaceuticals is also exploring combination regimens with existing checkpoint inhibitors to potentially extend the benefits of immuno‐oncology therapies to a broader patient population. Strategic partnerships with academic centers and contract research organizations support the company’s efforts to accelerate development timelines and refine clinical protocols.
Founded in 2008 and headquartered in Boston, Massachusetts, TNF Pharmaceuticals operates research facilities in both the United States and Europe. The company has built a multidisciplinary team of scientists and clinicians dedicated to understanding the complex role of TNF in disease processes. Over the past decade, it has raised multiple rounds of private financing, culminating in a successful initial public offering that provided capital to advance its most promising candidates toward late‐stage clinical evaluation.
Leadership at TNF Pharmaceuticals brings together seasoned executives and industry experts with extensive backgrounds in drug discovery, clinical development and regulatory affairs. The senior management team includes professionals who have held key roles at leading global biopharma companies, ensuring that corporate strategy is aligned with best practices for clinical execution, quality systems and commercialization planning. With a commitment to scientific rigor and patient‐centered innovation, the company seeks to address significant unmet medical needs and deliver new therapeutic options to patients worldwide.
AI Generated. May Contain Errors.
Free TNFA Stock Alerts